We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

178 hedge funds and large institutions have $2.08B invested in Mirum Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 76 increasing their positions, 42 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 17

81% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 42

16% more call options, than puts

Call options by funds: $7.97M | Put options by funds: $6.87M

14% more capital invested

Capital invested by funds: $1.82B → $2.08B (+$255M)

11% more funds holding

Funds holding: 160178 (+18)

0% more funds holding in top 10

Funds holding in top 10: 99 (0)

1.51% less ownership

Funds ownership: 113.24%111.73% (-1.5%)

Holders
178
Holders Change
+18
Holders Change %
+11.25%
% of All Funds
2.56%
Holding in Top 10
9
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.13%
New
35
Increased
76
Reduced
42
Closed
17
Calls
$7.97M
Puts
$6.87M
Net Calls
+$1.1M
Net Calls Change
-$99K
Name Holding Trade Value Shares
Change
Change in
Stake
MB
26
MPM BioImpact
Massachusetts
$19.2M +$6.14K +154 +0%
N
27
Nuveen
North Carolina
$19.2M +$3.4M +85,290 +21%
CCM
28
Cadian Capital Management
New York
$18.6M -$30.3M -759,407 -61%
Bank of America
29
Bank of America
North Carolina
$18.2M +$5.35M +134,108 +40%
PM
30
Prosight Management
Texas
$18.2M +$6.02M +151,025 +48%
Millennium Management
31
Millennium Management
New York
$17.8M +$7.58M +190,121 +72%
Axa
32
Axa
France
$16.6M +$3.03K +76 +0%
Northern Trust
33
Northern Trust
Illinois
$14.3M +$3.59M +90,119 +32%
WP
34
Woodline Partners
California
$12.9M +$5.08M +127,285 +62%
Charles Schwab
35
Charles Schwab
California
$12.8M +$684K +17,149 +6%
PCM
36
Penn Capital Management
Pennsylvania
$12.1M +$2.72M +68,093 +28%
Invesco
37
Invesco
Georgia
$11.1M +$19.4K +487 +0.2%
EAM
38
Erste Asset Management
Austria
$10.1M
Voloridge Investment Management
39
Voloridge Investment Management
Florida
$10M +$10.2M +256,779 New
Norges Bank
40
Norges Bank
Norway
$9.68M +$9.9M +248,157 New
Barclays
41
Barclays
United Kingdom
$9.59M +$432K +10,824 +5%
RHJA
42
Rice Hall James & Associates
California
$9.47M +$518K +12,981 +6%
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$8.91M +$1.52M +38,226 +20%
Two Sigma Investments
44
Two Sigma Investments
New York
$8.87M +$2.55M +63,933 +39%
Ensign Peak Advisors
45
Ensign Peak Advisors
Utah
$8.6M -$88.6K -2,220 -1%
Two Sigma Advisers
46
Two Sigma Advisers
New York
$8.01M +$1.02M +25,600 +14%
BBA
47
Baker Bros. Advisors
New York
$7.43M
AAP
48
Ardsley Advisory Partners
Connecticut
$7.41M +$399K +10,000 +6%
Ameriprise
49
Ameriprise
Minnesota
$7.15M +$6.7M +168,037 +1,098%
NCGI
50
Next Century Growth Investors
Minnesota
$6.41M +$6.56M +164,371 New

MIRM Hedge Fund Activity: Q3 2024 in Review

178 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q3 2024, worth a combined $2.08B — up 14% from $1.82B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new MIRM positions and 17 closed out — a net gain of 18 holders — while 76 added to existing stakes and 42 trimmed.

The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $29.6M. The largest seller was BVF Inc, cutting an estimated $51.6M.

  • 178 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q3 2024, up from 160 in Q2 2024.
  • Funds reported $2.08B of Mirum Pharmaceuticals stock for Q3 2024, up 14% quarter-over-quarter.
  • 35 funds opened new Mirum Pharmaceuticals positions in Q3 2024 and 17 closed out, a net change of +18 holders.
  • The largest Mirum Pharmaceuticals buyer in Q3 2024 was Lord, Abbett & Co, an estimated $29.6M added.
  • The largest Mirum Pharmaceuticals seller in Q3 2024 was BVF Inc, an estimated $51.6M sold.

Based on aggregated 13F filings for Q3 2024.